FDA Issues Complete Response Letter for Supernus' SPN-830 (Apomorphine) in Parkinson's Disease
核心洞察
The FDA issued a Complete Response Letter (CRL) for Supernus Pharmaceuticals' New Drug Application (NDA) for SPN-830 (apomorphine) for Parkinson's disease.
The CRL cites the need for additional review regarding product quality data and the master file for the infusion device.
Supernus plans to address the FDA's concerns and resubmit the NDA, with no clinical safety or efficacy issues identified.
Supernus Pharmaceuticals has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for SPN-830 (apomorphine). SPN-830 is an investigational apomorphine infusion device intended for the continuous treatment of motor fluctuations, specifically "off" episodes, in patients with Parkinson's disease (PD). The FDA's decision indicates that the application, in its current form, is not ready for approval.
The CRL highlighted two primary areas requiring further attention. The first concerns product quality data, for which Supernus recently submitted additional information that the FDA has yet to review. The second area pertains to the master file for the infusion device, which is proprietary to the device manufacturer. Supernus intends to collaborate with the device manufacturer to provide the necessary information and determine the steps for resubmitting the NDA.
No Clinical Safety or Efficacy Concerns Raised
Importantly, the FDA did not raise any clinical safety or efficacy issues as a prerequisite for approval. Furthermore, the FDA successfully completed a preapproval inspection of the device manufacturer’s facility in February 2024, suggesting confidence in the manufacturing process itself.
Supernus' Commitment to Parkinson's Disease Treatment
Jack Khattar, President & CEO of Supernus, stated the company's dedication to bringing SPN-830 to market as a crucial treatment option for PD patients experiencing motor fluctuations. Supernus is committed to working with the FDA to address the CRL and resubmit the NDA for SPN-830.
About SPN-830 and Parkinson's Disease
SPN-830 is designed to provide a continuous infusion of apomorphine, a dopamine receptor (搜索) agonist, to help manage motor fluctuations in Parkinson's disease. Motor fluctuations, characterized by "off" episodes, are a common and debilitating symptom of PD, significantly impacting patients' quality of life. Current treatments often involve oral medications, which can have fluctuating effects and may not provide consistent relief of symptoms throughout the day.
Supernus Pharmaceuticals' Focus
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Their portfolio includes treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (搜索), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. They are also developing new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.